Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus adalimumab monotherapy in active psoriatic arthritis
2015-004477-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Secukinumab monotherapy with Adalimumab monotherapy (2 arms). Primary endpoint: American College of Rheumatology 20 response. Started Nov 2016; status: completed.
02
Drugs
secukinumabadalimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2015-004477-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004477-32.